In the last 20 years, the global regulatory frameworks for drug assessment have been managing the challenges posed by using cellular products as new therapeutic tools. Currently, they are defined as “Advanced Therapy Medicinal Products”, comprising a large group of cellular types that either alone or in combination with gene and tissue engineering technology. They have the potential to change the natural course of still lethal or highly debilitating diseases, including cancers, opportunistic infections and chronic inflammatory conditions. Globally, more than 50 cell-based products have obtained market authorization. This overview describes the advantages and unsolved challenges on developing cells as innovative therapeutic vehicles. The main cell therapy players and the legal framework are discussed, starting from chimeric antigen receptor T-cells for leukaemia and solid tumours, dealing then with lymphocytes as potent anti-microbiological tools and then focusing on mesenchymal stem/stromal cells whose role covers regenerative medicine, immunology and anti-tumour therapy.

Developing cell therapies as drug products / Ciccocioppo, R.; Comoli, P.; Astori, G.; del Bufalo, F.; Prapa, M.; Dominici, M.; Locatelli, F.. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 178:2(2021), pp. 262-279. [10.1111/bph.15305]

Developing cell therapies as drug products

Prapa M.;Dominici M.;
2021

Abstract

In the last 20 years, the global regulatory frameworks for drug assessment have been managing the challenges posed by using cellular products as new therapeutic tools. Currently, they are defined as “Advanced Therapy Medicinal Products”, comprising a large group of cellular types that either alone or in combination with gene and tissue engineering technology. They have the potential to change the natural course of still lethal or highly debilitating diseases, including cancers, opportunistic infections and chronic inflammatory conditions. Globally, more than 50 cell-based products have obtained market authorization. This overview describes the advantages and unsolved challenges on developing cells as innovative therapeutic vehicles. The main cell therapy players and the legal framework are discussed, starting from chimeric antigen receptor T-cells for leukaemia and solid tumours, dealing then with lymphocytes as potent anti-microbiological tools and then focusing on mesenchymal stem/stromal cells whose role covers regenerative medicine, immunology and anti-tumour therapy.
2021
178
2
262
279
Developing cell therapies as drug products / Ciccocioppo, R.; Comoli, P.; Astori, G.; del Bufalo, F.; Prapa, M.; Dominici, M.; Locatelli, F.. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 178:2(2021), pp. 262-279. [10.1111/bph.15305]
Ciccocioppo, R.; Comoli, P.; Astori, G.; del Bufalo, F.; Prapa, M.; Dominici, M.; Locatelli, F.
File in questo prodotto:
File Dimensione Formato  
10.1111@bph.15305.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 901.71 kB
Formato Adobe PDF
901.71 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1239236
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact